Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Metsera (NASDAQ:MTSR) shares opened at $25 ...

Metsera’s investors include affiliates of ARCH Venture Partners, which had a 28.1% stake in the company prior to the offering, the filings show. Their stake is expected to fall to 23.5% after ...

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...

Jan 31 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab ... City-based biotech company highlights the growing investor interest in companies developing innovative ...

The offering is entirely comprised of shares offered by Metsera, which could signal that existing investors are not participating in the IPO, potentially raising concerns about their confidence in ...

Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...

Obesity-drug maker Metsera Inc.’s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their stock-market debuts ...